Skip to Content

Merck & Co Inc - Stock Quote MRK

Rating as of

Morningstar's Merck & Co Inc Stock Analysis

Valuation
Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price

PREMIUM

5-Star Price

PREMIUM

Economic Moat

PREMIUM

Capital Allocation

PREMIUM

Undervalued Merck Posts Strong Q1, Lifted by COVID Treatment Sales and Continued Keytruda Growth

Damien Conover, CFA Sector Director

Analyst Note

| Damien Conover, CFA |

Merck reported strong first-quarter results ahead of our projections, but we don’t expect any major changes to our fair value estimate. We view the stock as undervalued, with the market not fully appreciating the firm’s solid growth potential driven by immuno-oncology drug Keytruda, human papillomavirus vaccine Gardasil, and animal health drugs. The strong positioning of these products along with a robust portfolio and improving pipeline reinforces Merck’s wide moat.

Read Full Analysis

Merck & Co Inc's Company Profile

Business Description

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, close to half of the firm's sales are generated in the United States.

Contact
2000 Galloping Hill Road
Kenilworth, NJ, 07033
T +1 908 740-4000
Sector Healthcare
Industry Drug Manufacturers - General
Most Recent Earnings Mar 31, 2022
Fiscal Year End Dec 31, 2022
Stock Type Classic Growth
Employees 68,000

Merck & Co Inc's Related Articles & News